Key result
This editorial introduces the Trial of Preventing Hypertension (TROPHY) and discusses the high prevalence and long-term complications of prehypertension.
Why the study?
Does pharmacotherapy prevent hypertension in patients with prehypertension?
Does pharmacotherapy prevent hypertension in patients with prehypertension?
Answers are grounded in this paper and cite their sources.
This editorial discusses the implications of the TROPHY trial regarding the use of pharmacotherapy to prevent the progression of prehypertension to arterial hypertension.
Prehypertension, defined as the blood-pressure range of 120 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic, is present in about 70 million Americans.1,2 The condition heralds arterial hypertension and thus may be considered a starting point in the cardiovascular disease continuum. Because of its high prevalence and long-term complications, prehypertension has been estimated to decrease the average life expectancy by as much as five years.35 Unfortunately, current preventive strategies, although admirable from both individual and societal perspectives, are weak.In this issue of the Journal, the investigators of the Trial of Preventing Hypertension (TROPHY) . . .
No takes yet. Share an insight, caveat, or question.
Heribert Schunkert (2006) conducted an editorial in Prehypertension. This editorial introduces the Trial of Preventing Hypertension (TROPHY) and discusses the high prevalence and long-term complications of prehypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: